Drugs / US-Lantus
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06627478 Comparator | Oct 2024 → Jul 2025 | — | Xentria, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05248841 Comparator | Mar → Aug 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Lannett Company, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US-Lantus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05248841 ↗ |
| Route | Subcutaneous | “Lantus subcutaneously as a single morning dose” NCT05248841 ↗ |